Endo International plc. (Nasdaq: ENDP) Settles FTC Lawsuit – Shares Continue Slide

Endo International plc. – Nasdaq: ENDP 

Shares of Ireland-based Endo International plc. continue their 2017 slide. ENDP shares, traded on the Nasdaq, have lost around 1/3 of their value this year. Today Endo International settled allegations that Endo Pharmaceuticals violated antitrust law when it agreed to pay rivals Watson Laboratories and Impax to delay introducing generic versions of two painkillers. The FTC’s complaint, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleged that certain aspects of the Opana® ER and Lidoderm® settlements constituted unfair methods of competition in violation of federal law and sought injunctive and declaratory relief, as well as other remedies including restitution and disgorgement. 

Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications through its operating companies worldwide. 

Eighteen firms follow Endo International. Seven rate ENDP as a “Strong Buy”, one rates the shares a “Buy”, and ten rate ENDP as a “Hold”. The consensus price target is $20. 

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol ENDP
Last Price a/o 3:26 PM EST  $                    12.10
Average Volume 5.72 million
Market Cap $2.8 Billion
Sales $3.84 Billion
Shares Outstanding 233 million
Share Float 221.48 million
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 6.29%
Short Interest Ratio 2.43
Quarterly Return -37.96%
YTD Return -25.08%
Year Return -78.11%

Previous ArticleNext Article
Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Leave a Reply

Your email address will not be published. Required fields are marked *